ePrints

Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial

Lookup NU author(s): Rachel Donegan, Dr Sarah CrispORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publication metadata

Author(s): Greenland JC, Dresser K, Cutting E, Donegan R, Bond S, Crisp SJ, Scott KM, Voysey ZJ, Holbrook J, Kahanawita L, Pal R, Camacho M, Peattie ARD, Spindler LRB, Hong YT, Fryer TD, Williams-Gray CH

Publication type: Article

Publication status: Published

Journal: The Lancet Neurology

Year: 2026

Volume: 25

Issue: 1

Pages: 39-49

Print publication date: 01/01/2026

Online publication date: 10/12/2025

Acceptance date: 02/04/2018

Date deposited: 13/05/2026

ISSN (print): 1474-4422

ISSN (electronic): 1474-4465

Publisher: Elsevier Ltd

URL: https://doi.org/10.1016/S1474-4422(25)00386-2

DOI: 10.1016/S1474-4422(25)00386-2

Data Access Statement: The datasets generated during this trial can be made available on request to the AZA-PD trial management group, or the Chief Investigator where the trial management group is not available. Requests can be made to cuh.neurosciencecctu@nhs.net. Requests for access to the datasets will be considered after at least 6 months following publication of the trial results, until 10 years following the initial publication. All research data obtained from Cambridge University Hospitals NHS Trust/Cambridge University will be de-identified participant data. Consent to share de-identified participant data with investigators who are undertaking similar research projects was sought from participants during the informed consent process. Investigators will be required to have ethical approval for their project before sharing any de-identified participant data.

Altmetrics

Funding

Share